Anastasiya Sybirna

Anastasiya is a Senior Associate with F-Prime Capital’s London team, focusing on healthcare investments. She is a Board Observer for three European therapeutic platform companies: T-Therapeutics, Peptone and Shift Bioscience. Before joining F-Prime in 2022, Ana was an Engagement Manager at McKinsey in London, specializing in Pharmaceuticals & Medical Products. She had also worked as a Strategy Consultant at Advancy. Ana holds a Ph.D. in Stem Cell Biology and Medicine from the University of Cambridge (UK), an MSc in Molecular and Cell Biology from École normale supérieure (Paris, France), and a BSc in Biology from Ivan Franko National University of Lviv (Ukraine). Her Ph.D. research focused on using synthetic biology and in vitro models to study how transcription factors regulate early human germ cell development.